


# **ANNUAL ACCOUNTS**

for



**INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS**

ORG. NO  
802428-5986

THE FINANCIAL YEAR  
2016

## **Director's Declaration**

### **Purpose**

The purposes for which the Federation is formed are to advance efforts to lessen the suffering of people with psoriasis and to improve methods of treatment and research for finding the ultimate cause and cure of the disease. In order to realize its purposes, the Federation shall:

- Represent the interests of its member associations in international forums such as the World Health Organization, the World Congress of Dermatology and international psoriasis symposia. IFPA shall also in close cooperation with other relevant international organizations organize international conferences, symposia and other events related to psoriasis/psoriatic arthritis, e.g., The World Psoriasis Day.
- Provide advice and consultation on the problems associated with psoriasis to member organizations or other communities and organizations worldwide.
- Provide the basis for closer liaison and the free exchange of information among psoriasis organizations and related organizations worldwide.
- Encourage and assist the establishment of new national organizations of people with psoriasis.
- Contribute to the improvement of the quality of health and social life of people suffering from psoriasis and psoriatic arthritis.
- The Federation shall not supersede or contravene the autonomy of national or other member organizations.

### **Vision**

Achieve a world without suffering from psoriasis.

### **Mission**

Be the global psoriasis advocacy association, with a focus on empowering our members, improving living conditions for psoriasis patients, raising awareness and cooperating with fellow stakeholders.

### **Goals**

IFPA's goals as an organization are to:

- Empower national psoriasis organizations by uniting them, strengthening their work and acting as their global voice.
- Improve patients' living conditions by advocating for correct diagnosis, universal access to treatment and less discrimination and stigmatization.
- Raise psoriasis awareness through education, information and highlighting research results.
- Cooperate with relevant psoriasis stakeholders, including medical and pharmaceutical actors.

## **Governance**

IFPA is governed by the General Assembly (GA) of its Full members. The meeting of the General Assembly is held every three years, with the next to be held in 2019. According to the General Assembly's decision in June 2016, a structural change in IFPA was approved, meaning that IFPA has now a Board and not an Executive Committee anymore and that the Secretariat is now led by an Executive Director.

In furtherance of the objectives of the Federation, the IFPA Board shall implement IFPA policies and management between official General Assembly meetings. The IFPA Board may also call an Extraordinary General Assembly meeting, either as a physical meeting or by postal/online vote, should any urgent amendments to or clarifications of the IFPA Constitution or Bylaws be deemed necessary. In 2016 the IFPA Board had five meetings, of which three physical and two telemeetings.

## **IFPA Secretariat**

In order to assist the IFPA Board in its management of the Federation and its projects, a Secretariat was formed in 2007, and placed in Stockholm, Sweden. As per 2016 IFPA took over the employer liability from the Swedish Psoriasis Association, and run the organization independently.

IFPA decided to move its office to new premises in Alvik Strand which suited the organizations needs and requirements. During the first quarter of 2016 the IFPA Secretariat were comprised of three staff members. Due to IFPA's expansion of advocacy projects, number of member organizations, the importance to maintain its current level of activities and build a strong Communications function to raise the profile of IFPA globally, it was decided to strengthen and resource the Secretariat. A Communications Officer was employed in late spring and an Advocacy & Policy Officer was employed in late autumn.

## **Main activities 2016**

- IFPA Advocacy project
- World Psoriasis Day
- 5th World Psoriasis & Psoriatic Arthritis Conference 2018
- IFPA Member meeting
- Global Psoriasis Atlas
- Fundraising - IFPA Solidarity Fund

## **IFPA Advocacy project (UN/WHO)**

- Global, regional and national recognition for psoriasis as a chronic, serious non-communicable and disabling disease steps into its next phase as the WHO psoriasis resolution was adopted at the 67th World Health Assembly in May 2014.
- In early 2016, the WHO published a Global report on psoriasis, with contribution from IFPA and its members. This was a true milestone for the psoriasis community as this was WHO's first report on psoriasis. The report on psoriasis brings the public health impact on psoriasis into focus and highlights recommended actions for governments and policy-makers to control and prevent its complications. Furthermore, the report stresses the importance on actions for health systems, health professionals, patient organizations and civil society, who plays an important role in improving the lives for people living with psoriasis.

- Ensuring psoriasis steadily emerges as a global health issue requires coordinated and cross-sectoral action. In the light of this, IFPA initiated the Global Psoriasis Coalition project to continue meeting the needs of people with psoriasis worldwide. Following up to the Report, the Global Psoriasis Coalition aims to answer several key issues included in the Report, thus boosting rights-based global and local advocacy. The mission with the Global Psoriasis coalition is to act as the recognized, multi-stakeholder advocate for the improvement the living conditions of people with psoriasis. The Coalition's overarching objective is to promote psoriasis in the non-communicable diseases policy agenda in the period 2018-2020, with reference to the scheduled revision of the NCD Action Plan for 2018, and consequently 2020.
- The IFPA Advocacy project 2016 focused mainly on the IFPA Coalition Project (the implementation of the WHO psoriasis resolution and the recommendations of the WHO global report). Strengthen IFPA's role and position within the global disability movement (Platform II) and develop IFPA's strategic work within the Human Rights field, focusing on the stigmatization and discrimination aspects related to psoriasis, was not prioritized due to IFPA's re-organization and scarce personnel resources.

### **Actions in 2016**

#### ***Platform I: World Health Organization, WHO, Geneva***

- Further elaborated on improvement and expansion of the IFPA activities in the WHO Psoriasis Resolution implementation process – launch of the IFPA Coalition project
- Met with Permanent Missions in Geneva to follow-up on the implementation work of the WHO Psoriasis Resolution and the report
- Supported members in their advocacy work to implement the resolution and the recommendations in the report, in their countries – usage of IFPA Advocacy Toolkit
- Supported national health ministries to implement the resolution in their countries (where there is no patient association)
- Continue and follow-up regarding the provided campaign toolkit towards health ministries
- Participated in WHO meetings to ensure that the psoriasis community is represented and heard

#### ***Platform II: United Nations, UN, New York – disability***

IFPA established a connection with the CRPD Secretariat (Secretariat working on the Convention on the Rights of People with Disabilities). Based on this, in December 2016, IFPA was able to be featured in their monthly newsletter, introducing IFPA and the IFPA Coalition Project.

### ***External meetings***

IFPA was represented at several meetings, summits and conferences organized by the WHO as well as IFPA's regional members and partner meetings.

Examples of activities:

- Conference: American Academy of Dermatology, AAD
- Conference: First African Summit of Dermatology and Venereology, ASDV
- Conference: European Academy of Dermatology and Venereology, EADV (IFPA took part in the press conference, the patient village breakfast meeting and presented its work with focus on advocacy at the patient session)
- EFFCA meetings organized in February (Barcelona) and November (Brussels) 2016 with special emphasis on biosimilars
- 7th Global Patients Congress, International Alliance of Patient Organizations, IAPO
- Side Event organized by IFPA with the theme "A strong wind of change" during the World Health Assembly 2016
- WHO Regional CSO Consultation – establishment of an African Civil Society Organizations Network and development of a Regional Implementation Framework for the prevention and control of non-communicable disease (NCD's)

### **World Psoriasis Day 2016**

The theme for World Psoriasis Day 2016 was: "Breaking barriers for people with psoriasis. Every day, people with psoriasis face immense barriers in society, including in the healthcare system, at work, in school and in social relations. This leads to missed opportunities in life, which could have been prevented. After extensive advocacy efforts by IFPA, both a WHO Resolution on Psoriasis and the Global Report on Psoriasis are in place. Both documents highlight recommended actions for governments and policy-makers for the control and prevention of psoriasis and its complications.

### ***Core communication messages***

Fight - prejudices, stigmatization and discrimination

Raise - awareness, understanding and hope

Gain – access to proper diagnosis, treatment and quality of life

### ***Supporting messages***

- Psoriasis can be psychologically devastating. Many patients experience prejudice, stigmatization and discrimination. This negatively affects their daily lives.
- Raising awareness improves understanding of psoriasis as a disease. It also educates society on how to take action. This gives hope to the 125 million psoriasis patients worldwide.
- Patients' quality of life is vastly improved when they gain access to a proper diagnosis and treatment, through high-quality healthcare.

### ***Campaign - Breaking Barriers animated film***

IFPA created an animated film as the core of the World Psoriasis Day 2016 campaign. The film tells the story of Anna and Peter, who suffer from psoriasis and psoriatic arthritis. They are not alone: over 125 million people worldwide share their struggle. Every day, these patients have to overcome difficult barriers to access their basic human rights.

The animated film explains the importance to FIGHT the barriers of prejudice, stigma and discrimination and that on October 29, RAISE hope and awareness by spreading knowledge and understanding. The goal is for all patients to GAIN access to proper diagnosis and treatment, with improved life quality as a result. A wide range of World Psoriasis Day awareness-raising activities were carried out by IFPA's members all over the globe, from seminars to meetings with politicians and decision makers. Every year IFPA sees an increased interest in World Psoriasis Day and awareness raising activities taking place.

### **The 5<sup>th</sup> World Psoriasis & Psoriatic Arthritis Conference 2018**

In 2016 IFPA started the planning and preparation process for the World Psoriasis & Psoriatic Arthritis Conference, to be held in Stockholm in 2018. Its theme is: "Psoriasis – Science and Patients: Global Challenges and Future perspectives". Professor Mona Ståhle from Karolinska University Hospital, Sweden has been assigned as President of the upcoming conference.

The first announcement was made during spring and the conference has been promoted extensively throughout the year, at various conference and events, IFPA being represented at. These actions are to be continued during 2017 and last up until the start of the conference.

IFPA together with the congress bureau Meetagain, who was given the assignment as the PCO, professional conference organizer, initiated the conference project plan and timeline to be followed up until the execution of the conference. This to ensure that the conference meets the quality standards expected from international target groups and audiences within the disease area.

Just as with the previous conferences, IFPA's members were given the opportunity to suggest topics/issues that are felt to be highly relevant for the psoriasis community – be it locally, nationally, regionally or globally. Their suggestions were forwarded to the Scientific Executive Committee as well as the Organizing Committee for their respective evaluation and topics might be included in the conference programs.

### **IFPA Member meeting**

In June, IFPA had the great pleasure of welcoming the IFPA members to Lisbon, Portugal, for two full days of workshops, seminars and for the formal meeting of the IFPA General Assembly, which is held every third year. First day started with the IFPA Informal member meeting and the workshop "back to basic", aimed at looking what IFPA has done in the past and identifying the unmet needs for the future. IFPA's members were given the opportunity to express their expectations from IFPA the coming years.

Next workshop of the day "From global policy to national action – using advocacy to move psoriasis up on the national health agenda" focused on the implementation of the WHO resolution and WHO global report on psoriasis, and psoriasis being a non-communicable disease (NCD). It was communicated that there has been a shift in the global health agenda and increased focus on NCD's and that IFPA should act on the momentum and try to advocate for psoriasis to be the fifth largest NCD. Information was also presented about the NCD Alliance and that IFPA should look at other organizations and see how they work. The session ended by a presentation on IFPA's Advocacy Toolkit developed for IFPA members to use. It emphasized on the need for developing an advocacy strategy and why such a strategy is important. The informal IFPA member meeting concluded by a presentation on psoriasis treatment in pipeline, held by

Professor Mona Ståhle, Karolinska University Hospital.

The formal meeting, IFPA General Assembly, commenced by a presentation of the formal meeting agenda and a chairman, secretary and two-minute checkers being elected. It was followed by the General Assembly being asked to approve the IFPA Activity report, IFPA Financial report and Auditors report 2013-2015. Two proposals on amendments to the IFPA Constitution were put forward by the IFPA Board to be voted upon. After that, reports were presented from the Chairmen of the IFPA Committees followed by approval of the IFPA membership fee for the next three-year period.

Last part of the formal meeting focused on the election of the IFPA Board for the next three-year period and the election of Auditor and supplement Auditor.

Day two started with reporting about of 2015's World Psoriasis Day theme and messaging and presenting the campaign for 2016. It was followed by presentations held by IFPA's corporate partners. Second part of the meeting focused on the IFPA Advocacy Toolkit (part two) "Driving national implementation of the resolution". It aimed at discussing the content of the WHO resolution and the WHO report on psoriasis and try to define a strategy for implementing it nationally and what messages needs to be leverage. Next session focused on psoriasis: in the context of Human Rights and disability, with the aim to point to the burden of psoriasis as diminished quality of life etcetera. Results of two surveys of attitudes towards psoriasis patients were presented, showing the discrimination and stigmatization psoriasis patient's face in their daily life. The session ended by informing the IFPA members about the Convention of Rights for People with Disabilities and that is the Governments responsibilities to overlook, follow these conventions and put them into a social context, including persons with disabilities in the society and fight and stop discrimination and stigmatization. The meeting day was concluded with an update/progress report on the Global Psoriasis Atlas project and the World Psoriasis & Psoriatic Arthritis Conference 2018.

## **Members**

On December 31<sup>st</sup>, IFPA had fifty-four Full member organizations and one Associated member organization. Two new members joined IFPA during 2016: Serbia and Georgia.

## **Memberships**

IFPA became a member of the NCD Alliance 2016. IFPA is a Full member of the International Alliance of Patients' Organizations (IAPO) since 2012 and a member of the Noncommunicable Diseases Alliance Common Interest Group since 2011.

## **The Global Psoriasis Atlas**

The Board of Governors, IFPA, the International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC), initiated the Global Psoriasis Atlas, GPA, in 2015 and have continuously worked with the structure of the project including legal entities, academic institution alignment, contractive and flow and indicative budgets. Workstreams have been developed with mission to focus on:

- Workstream 1: conduct systematic review of current available literature with the desired outcome of a publication in suitable high impact journals
- Workstream 2: determine a methodology to serve the framework for compiling the Global Psoriasis Atlas, thus providing a standard operating procedure to execute the GPA under a "hub and spoke" model

The project was launched on September 28th at the EADV Conference, in Vienna, one of the largest European Congresses in Dermatology and Venereology. It was communicated that the GPA is now a reality and that the consortium is a functioning entity working on the planning of the project. The first phase of the project is to start early 2017 and to focus on gathering the existing data about psoriasis mostly in Europe and USA.

Project funding was confirmed from several partners, ensuring part project financial stability. A collaboration agreement and other documents were drafted to determine the roles and responsibilities of respective party. Future key actions will be to decide on the position of Programme Director, find solution to be found regarding some potential funding for the administrative work/support of IFPA.

### **Corporate Partners**

In 2016 IFPA received project support from the following corporate partners: AbbVie, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer and Amgen.

IFPA was also represented at several meetings hosted by the corporate partners. IFPA had the opportunity to present its work with special emphasis on advocacy as well as influencing the agenda and present the global voice of the patients:

- The European Patient Innovation Summit (Novartis)
- NY Skin (Leo Pharma)
- WPD Twitter chat (together with AbbVie)
- The Psoriasis Academy (Leo Pharma)

### **Fundraising/IFPA Solidarity Fund**

In the autumn, IFPA launched the IFPA Solidarity Fund, a new project aimed to address the everyday funding gap IFPA's members face, and to award grants to support psoriasis advocacy, education and awareness-raising. The IFPA Solidarity Fund was set up through voluntary contributions by IFPA supporters, IFPA members and other actors. A first application call was sent out and IFPA to grant small-scale projects up to 1500 EUR per project in early 2017.

### **Administration report**

The Board of International Federation of Psoriasis Associations (IFPA) hereby delivers the annual account for the financial year 2016-01-01 – 2016-12-31.

#### ***Accounting and valuation principles***

The annual account has been prepared in accordance with the Swedish Accounting Act.

Regarding the results and financial position, please refer to the attached financial statements and accompanying notes.



Org. no 802428-5986

Profit and loss account	2016-01-01		2015-01-01	
	2016-12-31		2015-12-31	
	SEK	EUR	SEK	EUR
<b>Income</b>		9,4704		9,3562
Membership fees	77 697	8 204	78 203	8 358
Donations	0	0	95 091	10 163
Rounding- off to whole kronor	6	1	1	0
Amount WPC	904 655	95 524	0	0
Participation fees	66 258	6 996	3 270	350
Refunds and reimbursement	540 432	57 065	28 017	2 994
Jansen Cilag	323 284	34 136	355 265	37 971
AbbVie	834 588	88 126	780 530	83 424
LEO Pharma A/S	599 456	63 298	608 946	65 085
Novartis	1 004 741	106 093	625 920	66 899
Eli Lilly	600 457	63 404	333 585	35 654
Pfizer	334 842	35 357	608 290	65 015
Celgene	620 984	65 571	603 044	64 454
Other operating income	-711 975	-75 179	0	0
<b>Total income</b>	<b>5 195 424</b>	<b>548 596</b>	<b>4 120 161</b>	<b>440 367</b>
<b>Costs</b>				
Outgoing donations	0	0	-500	-53
Office rental agreement	-394 886	-41 697	-3 020 412	-322 825
Freight and transport	-2 655	-280	-13 452	-1 438
Conference costs	-167 963	-17 736	-88 988	-9 511
Telemeetings	-6 697	-707	-3 934	-420
Travel costs	-362 594	-38 287	-418 363	-44 715
Refund members	-187 855	-19 836	0	0
Hotel costs	-240 825	-25 429	-145 802	-15 583
Food	-82 019	-8 661	-50 573	-5 405
Reimbursement	-44 455	-4 694	-78 416	-8 381
Printing costs	-56 289	-5 944	-90 299	-9 651
PR-Marketing	-9 979	-1 054	-98 027	-10 477
Entertainment, deductible	0	0	-180	-19
Entertainment, non-deductible	0	0	-93	-10
Gifts	-2 288	-242	-9 202	-984
Office material	-80 806	-8 533	-38 419	-4 106
Phone	-28 960	-3 058	-2 533	-271
Insurance for the organisation	-6 741	-712	-1 096	-117
Losses on receivables	-9 560	-1 009	-1 050	-112
Accountant and audit	-299 123	-31 585	-111 563	-11 924
Consultants	-381 339	-40 266	-79 188	-8 464
Web	-173 886	-18 361	-155 847	-16 657
Newsservice	-68 550	-7 238	0	0
Bank fees	-14 912	-1 575	-8 477	-906
Wire transaction fees	0	0	-254	-27
Membership fees	-5 843	-617	-3 966	-424
Subscriptions and articles	0	0	-4 210	-450
Interest income tax account	11	1	0	0
Interest taxes and fees	-100	-11	0	0
Staff costs	-2 191 094	-231 362	0	0
Cost of interest	0	0	2	0
Exchange profit/loss	18 065	1 908	28 399	3 035
Other operating expenses	523 808	55 310	0	0
<b>Total costs</b>	<b>-4 277 535</b>	<b>-451 674</b>	<b>-4 396 444</b>	<b>-469 896</b>
<b>Profit (+) / Loss (-)</b>	<b>917 889</b>	<b>96 922</b>	<b>-276 283</b>	<b>-29 529</b>

Costs per activity	2016-01-01		2015-01-01	
	2016-12-31		2015-12-31	
	SEK	EUR	SEK	EUR
		9,4704		9,3562
<b>1. WPC</b>				
Freight and transport	0	0	-5 194	-555
Travel costs	0	0	-123 425	-13 192
Hotel costs	0	0	-128	-14
Food	0	0	-8 955	-957
Reimbursement	0	0	-18 329	-1 959
Printing costs	-2 275	-240	-29 238	-3 125
PR-Marketing	0	0	-65 977	-7 052
Gifts	0	0	-8 560	-915
Office material	0	0	-785	-84
Consultants	0	0	-12 000	-1 283
Web	-1 098	-116	-198	-21
Bank fee	0	0	-452	-48
Other operating expenses	523 808	55 310	0	0
<b>Total costs</b>	<b>520 435</b>	<b>54 954</b>	<b>-273 240</b>	<b>-29 204</b>
<b>2. World Psoriasis Day</b>				
Conference costs	-130 035	-13 731	-28 996	-3 099
Travel costs	-100 626	-10 625	0	0
Refund members	-183 685	-19 396	0	0
Hotel costs	-96 652	-10 206	0	0
Food	-40 243	-4 249	0	0
Reimbursement	-817	-86	0	0
Printing costs	-12 771	-1 349	-14 562	-1 556
PR-Marketing	0	0	-31 250	-3 340
Gifts	-1 288	-136	0	0
Office material	-360	-38	0	0
Losses on receivables	-9 560	-1 009	0	0
Consultants	-28 125	-2 970	0	0
Web	0	0	-20 866	-2 230
Exchange profit/loss	-44	-5	0	0
<b>Total costs</b>	<b>-604 205</b>	<b>-63 799</b>	<b>-95 673</b>	<b>-10 226</b>
<b>3. Social Media Projects *</b>				
Travel costs	0	0	-11 040	-1 180
Reimbursement	0	0	-2 627	-281
<b>Total costs</b>	<b>0</b>	<b>0</b>	<b>-13 667</b>	<b>-1 461</b>
<b>4. EADV</b>				
Conference costs	-23 919	-2 526	-49 738	-5 316
Travel costs	-16 697	-1 763	-84 511	-9 033
Hotel costs	-24 702	-2 608	-47 274	-5 053
Food	0	0	-10 082	-1 078
Reimbursement	-5 320	-562	-5 809	-621
Printing costs	0	0	-3 737	-399
<b>Total costs</b>	<b>-70 637</b>	<b>-7 459</b>	<b>-201 152</b>	<b>-21 499</b>

Costs per activity	2016-01-01 2016-12-31		2015-01-01 2015-12-31	
	SEK	EUR	SEK	EUR
		9,4704		9,3562
<b>5. External Meetings</b>				
Conference costs	-7 158	-756	-3 425	-366
Travel costs	-58 120	-6 137	0	0
Hotel costs	-45 633	-4 818	0	0
Food	-1 718	-181	0	0
Reimbursement	-3 740	-395	0	0
PR-Marketing	-4 977	-526	0	0
<b>Total costs</b>	<b>-121 345</b>	<b>-12 813</b>	<b>-3 425</b>	<b>-366</b>
<b>6. EC Meetings</b>				
Freight and transport	-609	-64	0	0
Conference costs	-3 403	-359	0	0
Telemeetings	-1 899	-201	0	0
Travel costs	-109 194	-11 530	-53 130	-5 679
Hotel costs	-33 060	-3 491	-20 532	-2 194
Food	-27 371	-2 890	-12 223	-1 306
Reimbursement	-16 754	-1 769	-17 013	-1 818
Representation, deductible	0	0	-180	-19
Representation, non-deductible	0	0	-93	-10
Web	-6 885	-727	0	0
<b>Total costs</b>	<b>-199 175</b>	<b>-21 031</b>	<b>-103 171</b>	<b>-11 027</b>
<b>7. Psoriasis Atlas</b>				
Travel costs	0	0	-22 974	-2 456
Printing costs	0	0	-5 869	-627
Consultants	-8 807	-930	0	0
<b>Total costs</b>	<b>-8 807</b>	<b>-930</b>	<b>-28 843</b>	<b>-3 083</b>
<b>8. Advocacy</b>				
Conference costs	-1 450	-153	-6 829	-730
Travel costs	-57 136	-6 033	-52 764	-5 639
Hotel costs	-38 079	-4 021	-39 871	-4 261
Food	-4 942	-522	-73	-8
Reimbursement	-17 425	-1 840	-22 966	-2 455
Printing costs	-30 107	-3 179	-16 856	-1 802
Office material	-420	-44	-281	-30
Phone	0	0	-1 979	-212
Consultants	-69 085	-7 295	0	0
Bank fees	-120	-13	-134	-14
Wire transaction fees	0	0	-125	-13
<b>Total costs</b>	<b>-218 764</b>	<b>-23 100</b>	<b>-141 878</b>	<b>-15 164</b>
<b>9. Under the Spotlight</b>				
PR-Marketing	0	0	-800	-86
Web	-30 963	-3 269	-35 731	-3 819
<b>Total costs</b>	<b>-30 963</b>	<b>-3 269</b>	<b>-36 531</b>	<b>-3 904</b>

Costs per activity	2016-01-01		2015-01-01	
	2016-12-31		2015-12-31	
	SEK	EUR	SEK	EUR
		9,4704		9,3562
<b>10. IFPA</b>				
Outgoing donations	0	0	-500	-53
Office rental agreement	-394 886	-41 697	-3 020 412	-322 825
Freight and transport	-2 046	-216	-8 258	-883
Conference costs	-1 998	-211	0	0
Telemeetings	-4 797	-507	-3 934	-420
Travel costs	-20 823	-2 199	-70 519	-7 537
Refund members	-4 169	-440	0	0
Hotel costs	-2 700	-285	-37 997	-4 061
Food	-7 745	-818	-19 240	-2 056
Reimbursement	-399	-42	-11 673	-1 248
Printing costs	-11 136	-1 176	-20 038	-2 142
PR-Marketing	-5 002	-528	0	0
Gifts	-1 000	-106	-642	-69
Office material	-80 026	-8 450	-37 353	-3 992
Phone	-28 960	-3 058	-554	-59
Insurance for the organisation	-6 741	-712	-1 096	-117
Bad debt loss	0	0	-1 050	-112
Accountant and audit	-299 123	-31 585	-111 563	-11 924
Consultants	-147 675	-15 593	-67 188	-7 181
Web	-134 939	-14 249	-99 053	-10 587
Newsservice	-68 550	-7 238	0	0
Bank fees	-14 792	-1 562	-7 892	-843
Wire transaction fees	0	0	-129	-14
Membership fees	-5 843	-617	-3 966	-424
Subscription and articles	0	0	-4 210	-450
Salary costs	-2 191 094	-231 362	0	0
Interest income tax account	11	1	0	0
Cost of interest	0	0	2	0
Interest expenses for taxes and fees	-100	-11	0	0
Exchange profit/loss	18 108	1 912	28 399	3 035
<b>Total costs</b>	<b>-3 416 427</b>	<b>-360 748</b>	<b>-3 498 865</b>	<b>-373 962</b>
<b>13. Global Psoriasis Coalition</b>				
Consultants	-127 646	-13 478	0	0
<b>Total costs</b>	<b>-127 646</b>	<b>-13 478</b>	<b>0</b>	<b>0</b>

\* From 2015 the IFPA chart of accounts were revised and new cost centers were made:

### 3. Social media project:

Costs for social media project are included under other projects from 2016.

Costs for social media project are declared under project 3 for year 2015.

These cost centers didn't have any costs year 2016 and 2015:

11. Africa project

12. IFPA Solidarity Fund

These cost centers weren't used during year 2015 and during year 2016 they were deleted:

30. Madrid 2013

31. Buenos Aires

32. EC Meetings

33. Psoriasis Atlas

## Balance sheet

2016-01-01

2015-01-01

2016-12-31

2015-12-31

		SEK	EUR	SEK	EUR
<b>Bank assets and claims</b>	<b>Notes</b>		9,5669		9,135
Outstanding claims	1	1 905 029	199 127	601 725	65 870
Other claims		2	0	0	0
Prepaid expenses and accrued income	2	930 034	97 214	77 790	8 516
Cash		6 381	667	476	52
Bank Nordea		5 983 011	625 387	3 009 152	329 409
<b>Total bank assets and claims</b>		<b>8 824 457</b>	<b>922 395</b>	<b>3 689 143</b>	<b>403 847</b>

**Capitals and creditors**


Capital		3 057 419	319 583	3 333 702	364 937
Profit or loss		2 651 223	277 125	-276 283	-30 244
Outstanding debts		45 866	4 794	0	0
Other debts		333 859	34 897	0	0
Prepaid income	3	2 580 261	269 707	601 725	65 870
Prepaid costs and fee paid in advance	4	155 830	16 288	30 000	3 284
<b>Total capital and creditors</b>		<b>8 824 457</b>	<b>922 395</b>	<b>3 689 143</b>	<b>403 847</b>

Notes	2016-01-01		2015-01-01	
	2016-12-31		2015-12-31	
	SEK	EUR	SEK	EUR
		9,5669		9,135
<b>Note 1 Outstanding claims</b>				
Mariana Guerreiro	908 856	95 000	0	0
Novartis Pharma AG	364 465	38 096	0	0
LEO Pharma A/S	631 709	66 031	601 725	65 870
<b>Total</b>	<b>1 905 029</b>	<b>199 127</b>	<b>601 725</b>	<b>65 870</b>
<b>Note 2 Prepaid expenses and accrued income</b>				
Alviks Strand kontorshotell	61 034	6 380	77 790	8 516
Loopia	198	21	0	0
Europeiska ERV	5 474	572	0	0
Verb Media Ltd	4 656	487	0	0
IFPA Invoice 3176	334 842	35 000	0	0
IFPA Membership "Brazil" 2016	22	2	0	0
Other operating expenses	523 808	54 752	0	0
<b>Total</b>	<b>930 034</b>	<b>97 214</b>	<b>77 790</b>	<b>8 516</b>
<b>Note 3 Prepaid income</b>				
LEO Pharma A/S	631 709	66 031	601 725	65 870
MCI Scandinavia AB	75 976	7 942	0	0
Psoriasis Association of Kenya	636	66	0	0
Eli Lilly & Company Ltd	246 260	25 741	0	0
Mariana Guerreiro	908 856	95 000	0	0
Almirall S.A.	4 850	507	0	0
Other operating income	711 975	74 421	0	0
<b>Total</b>	<b>2 580 261</b>	<b>269 707</b>	<b>601 725</b>	<b>65 870</b>
<b>Note 4 Prepaid costs and fee paid in advance</b>				
PwC	0	0	30 000	3 284
Hummelklappen	30 000	3 136	0	0
Nordea invoice 2302147599	2 110	221	0	0
Nordea invoice 2302147599	2 612	273	0	0
Nordea invoice 2302147599	18 045	1 886	0	0
Bergs School of Communication	103 063	10 773	0	0
<b>Total</b>	<b>155 830</b>	<b>16 288</b>	<b>30 000</b>	<b>3 284</b>


Stockholm 2017-0522




Lars Ettarp  
President




Hoseah Waweru  
Vice President



Silvia Fernandez Barrio  
Secretary




Josef de Guzman  
Treasurer



Ingvar Ingvarsson  
Member at Large

Stockholm 2017-0526



Tommy Nilsson  
Approved Public Accountant



## Revisionsberättelse

# Till föreningsstämman i International Federation of Psoriasis Associations

Org.nr 802428-5986

## Rapport om årsbokslutet

### *Uttalanden*

Vi har utfört en revision av årsbokslutet för 2016.

Enligt vår uppfattning har årsbokslutet upprättats i enlighet med bokföringslagen och ger en i alla väsentliga avseenden rättvisande bild av föreningens finansiella ställning per den 31 december 2016 och av dess finansiella resultat för året enligt bokföringslagen. Förvaltningsberättelsen är förenlig med årsbokslutets övriga delar.

### *Grund för uttalanden*

Vi har utfört revisionen enligt International Standards on Auditing (ISA) och god revisionssed i Sverige. Vårt ansvar enligt dessa standarder beskrivs närmare i avsnittet *Revisorns ansvar*. Vi är oberoende i förhållande till föreningen enligt god revisorssed i Sverige och har i övrigt fullgjort vårt yrkesetiska ansvar enligt dessa krav.

Vi anser att de revisionsbevis vi har inhämtat är tillräckliga och ändamålsenliga som grund för våra uttalanden.

### *Annan information än årsbokslutet*

Det är styrelsen som har ansvaret för den andra informationen. Den andra informationen består av inledning och Verksamhetsredovisning. Vårt uttalande avseende årsbokslutet omfattar inte denna information och vi gör inget uttalande med bestyrkande avseende denna andra information.

I samband med vår revision av årsbokslutet är det vårt ansvar att läsa den information som identifieras ovan och överväga om informationen i väsentlig utsträckning är oförenlig med årsbokslutet. Vid denna genomgång beaktar vi även den kunskap vi i övrigt inhämtat under revisionen samt bedömer om informationen i övrigt verkar innehålla väsentliga felaktigheter.

Om vi, baserat på det arbete som har utförts avseende denna information, drar slutsatsen att den andra informationen innehåller en väsentlig felaktighet, är vi skyldiga att rapportera detta. Vi har inget att rapportera i det avseendet.

### *Styrelsens ansvar*

Det är styrelsen som har ansvaret för att årsbokslutet upprättas och att den ger en rättvisande bild enligt bokföringslagen. Styrelsen ansvarar även för den interna kontroll som den bedömer är nödvändig för att upprätta ett årsbokslut som inte innehåller några väsentliga felaktigheter, vare sig dessa beror på oegentligheter eller på fel.

Vid upprättandet av årsbokslutet ansvarar styrelsen för bedömningen av föreningens förmåga att fortsätta verksamheten. De upplyser, när så är tillämpligt, om förhållanden som kan påverka förmågan





att fortsätta verksamheten och att använda antagandet om fortsatt drift. Antagandet om fortsatt drift tillämpas dock inte om beslut har fattats om att avveckla verksamheten.

#### *Revisorns ansvar*

Våra mål är att uppnå en rimlig grad av säkerhet om huruvida årsbokslutet som helhet inte innehåller några väsentliga felaktigheter, vare sig dessa beror på oegentligheter eller på fel, och att lämna en revisionsberättelse som innehåller våra uttalanden. Rimlig säkerhet är en hög grad av säkerhet, men är ingen garanti för att en revision som utförs enligt ISA och god revisionssed i Sverige alltid kommer att upptäcka en väsentlig felaktighet om en sådan finns. Felaktigheter kan uppstå på grund av oegentligheter eller fel och anses vara väsentliga om de enskilt eller tillsammans rimligen kan förväntas påverka de ekonomiska beslut som användare fattar med grund i årsbokslutet.

Som del av en revision enligt ISA använder vi professionellt omdöme och har en professionellt skeptisk inställning under hela revisionen. Dessutom:

- identifierar och bedömer vi riskerna för väsentliga felaktigheter i årsbokslutet, vare sig dessa beror på oegentligheter eller på fel, utformar och utför granskningsåtgärder bland annat utifrån dessa risker och inhämtar revisionsbevis som är tillräckliga och ändamålsenliga för att utgöra en grund för våra uttalanden. Risken för att inte upptäcka en väsentlig felaktighet till följd av oegentligheter är högre än för en väsentlig felaktighet som beror på fel, eftersom oegentligheter kan innefatta agerande i maskopi, förfalskning, avsiktliga utelämnanden, felaktig information eller åsidosättande av intern kontroll.
- skaffar vi oss en förståelse av den del av föreningens interna kontroll som har betydelse för vår revision för att utforma granskningsåtgärder som är lämpliga med hänsyn till omständigheterna, men inte för att uttala oss om effektiviteten i den interna kontrollen.
- utvärderar vi lämpligheten i de redovisningsprinciper som används och rimligheten i styrelsens uppskattningar i redovisningen och tillhörande upplysningar.
- drar vi en slutsats om lämpligheten i att styrelsen använder antagandet om fortsatt drift vid upprättandet av årsbokslutet. Vi drar också en slutsats, med grund i de inhämtade revisionsbevisen, om huruvida det finns någon väsentlig osäkerhetsfaktor som avser sådana händelser eller förhållanden som kan leda till betydande tvivel om föreningens förmåga att fortsätta verksamheten. Om vi drar slutsatsen att det finns en väsentlig osäkerhetsfaktor, måste vi i revisionsberättelsen fästa uppmärksamheten på upplysningarna i årsbokslutet om den väsentliga osäkerhetsfaktorn eller, om sådana upplysningar är otillräckliga, modifiera uttalandet om årsbokslutet. Våra slutsatser baseras på de revisionsbevis som inhämtas fram till datumet för revisionsberättelsen. Dock kan framtida händelser eller förhållanden göra att en förening inte längre kan fortsätta verksamheten.
- utvärderar vi den övergripande presentationen, strukturen och innehållet i årsbokslutet, däribland upplysningarna, och om årsbokslutet återger de underliggande transaktionerna och händelserna på ett sätt som ger en rättvisande bild.

Vi måste informera styrelsen om bland annat revisionens planerade omfattning och inriktning samt tidpunkten för den. Vi måste också informera om betydelsefulla iakttagelser under revisionen, däribland de betydande brister i den interna kontrollen som vi identifierat.



## Rapport om andra krav enligt lagar och andra författningar

### *Uttalande*

Utöver vår revision av årsbokslutet har vi även utfört en revision av styrelsens förvaltning för år 2016. Vi tillstyrker att föreningsstämman beviljar styrelsens ledamöter ansvarsfrihet för räkenskapsåret.

### *Grund för uttalande*

Vi har utfört revisionen enligt god revisionsred i Sverige. Vårt ansvar enligt denna beskrivs närmare i avsnittet *Revisorers ansvar*. Vi är oberoende i förhållande till föreningen enligt god revisorsred i Sverige och har i övrigt fullgjort vårt yrkesetiska ansvar enligt dessa krav.

Vi anser att de revisionsbevis vi har inhämtat är tillräckliga och ändamålsenliga som grund för vårt uttalande.

### *Styrelsens ansvar*

Det är styrelsen som har ansvaret för förvaltningen.

### *Revisorers ansvar*

Vårt mål beträffande revisionen av förvaltningen, och därmed vårt uttalande om ansvarsfrihet, är att inhämta revisionsbevis för att med en rimlig grad av säkerhet kunna bedöma om någon styrelseledamot i något väsentligt avseende företagit någon åtgärd eller gjort sig skyldig till någon försummelse som kan föranleda ersättningsskyldighet mot föreningen.

Rimlig säkerhet är en hög grad av säkerhet, men ingen garanti för att en revision som utförs enligt god revisionsred i Sverige alltid kommer att upptäcka åtgärder eller försummelser som kan föranleda ersättningsskyldighet mot föreningen.

Som en del av en revision enligt god revisionsred i Sverige använder vi professionellt omdöme och har en professionellt skeptisk inställning under hela revisionen. Granskningen av förvaltningen grundar sig främst på revisionen av räkenskaperna. Vilka tillkommande granskningsåtgärder som utförs baseras på vår professionella bedömning med utgångspunkt i risk och väsentlighet. Det innebär att vi fokuserar granskningen på sådana åtgärder, områden och förhållanden som är väsentliga för verksamheten och där avsteg och överträdelser skulle ha särskild betydelse för föreningens situation. Vi går igenom och prövar fattade beslut, beslutsunderlag, vidtagna åtgärder och andra förhållanden som är relevanta för vårt uttalande om ansvarsfrihet.

Stockholm 2017 -05-26

Tommy Nilsson

Auktoriserad revisor



To the board of directors of the International Federation of Psoriasis Associations

Stockholm May 24 2017

We have audited the annual report of International Federation of Psoriasis Associations, including a balance sheet, income statement and a review of the bookkeeping practices, as of December 31, 2016. This report summarizes the findings from this year's audit.

The audit progressed smoothly, and all the material errors that we identified during the course of the audit were corrected at the end and no material errors were left when the audit was completed.

### **Rules for allowances**

We have acknowledged that the allowance given to board members for traveling abroad in work related matters is standardized and amounts to 100 USD per day.

IFPA is an association that has its residence in Sweden and for that reason the rules in Sweden for allowances should be applied. The Swedish tax authority has stated a specific amount that is non-taxable and the amount depends on which country you travel. If the allowance is more than the pre-stated amount from the tax authority the amount exceeding the non-taxable amount is regarded as salary and is taxed with social security tax and SINK (special income tax).

We recommend that the board of directors change its routine regarding traveling allowances and follow the Swedish rules of setting the amount for the allowances.

### **Supporting documents for traveling in service**

When auditing the accounting records for traveling expenses, we noticed that some accounting records for those expenses was missing. It is important that you have a receipt or an invoice as supporting documentation. Furthermore, the purpose of the trip, including activity reports with clear specification of what has been done during the trip. The traveling participants also need to be clearly documented in the accounting records.

We recommend that the board of directors take action to secure that the accounting records related to traveling expenses comply with the bookkeeping act. For that reason, we recommend using an expense report for each employee, where the travel expenses is disclosed with: dates, purpose for taking the trip and the total expenses incurred for making the trip.

### **Revenue recognition**

In 2016, the association received a contribution for the IFPA conference, which is held every three years. In this year's financial statements, two thirds of this contribution was reported as deferred revenue.

The contribution should be recognized as revenue the year the conference is held. This error has been corrected in the annual accounts as described above.



**Accrual accounting regarding profit center**

Concerning our exam of the association's cost center and project accounting, we have noted that some of the ongoing projects shows both a profit and loss as of December 31<sup>st</sup> 2016. Due to that, the result for these projects has been accrued to receive a more accurate statement for the association as a whole.

Furthermore, we have noted that not all expenses related to the association's projects have been accounted for with a reference to the correct cost center.

We recommend that the board of director's exams its accounting procedures when using cost centers to ensure that revenue and expenses are being accounted for in a correct manner.

Stockholm May 24, 2017

Tommy Nilsson  
Authorized public accountant